Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxytocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR known ✓ | P30559 | 12/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 6/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 5/20 | 1.00 |
| ▸ | AVPR1B | P47901 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxytocin SCHEMBL21527573 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL14085374 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL20707334 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL29048 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL16373316 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL8370159 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL2126148 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL5110121 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL1661474 | 0.98 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL19303330 | 0.98 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256161-A9 | Methods and Compositions for Treating a Disease Condition in a Subject | Palo Alto Investors LP | 2023-08-17 | — | — | US | disclosed |
| US-11382513-B2 | Methods and compositions for treating a condition in a subject | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210121625-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | YUN ANTHONY JOONKYOO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200360271-A1 | Methods and Compositions for Treating a Renal Disease Condition in a Subject | Palo Alto Investors LP | 2020-11-19 | — | — | US | disclosed |
| US-10716749-B2 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS (US) | 2020-07-21 | — | — | US | disclosed |
| US-20180125419-A1 | Methods and Compositions for Treating a Condition in a Subject | PALO ALTO INVESTORS | 2018-05-10 | — | — | US | disclosed |
| CN-106692228-A | Application of sodium aescinate in preparation of spasmolysis drug for treating uterine smooth muscle | 武汉爱民制药股份有限公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-104042609-B | A kind of sesterterpene lactone compound purposes in preparation spasmolysis medicine | 武汉联合药业有限责任公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20140350041-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | PALO ALTO INVESTORS | 2014-11-27 | — | — | US | disclosed |
| US-8788041-B2 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2013116061-A1 | INSERTION AND REMOVAL METHODS AND APPARATUS FOR THERAPEUTIC DEVICES | FORSIGHT VISION4, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2012161746-A1 | USE OF OXYTOCIN OR OXYTOCIN ANALOGUES TO TREAT OBESITY AND DIABETES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20110029030-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | PALO ALTO INVESTORS | 2011-02-03 | — | — | US | disclosed |
| US-20070112327-A1 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS | 2007-05-17 | — | — | US | disclosed |
| EP-1735342-A2 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS | Compugen USA, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060116721-A1 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS | 2006-06-01 | — | — | US | disclosed |
| WO-2005107364-A9 | POLYNUCLEOTIDE, POLYPEPTIDES, AND DIAGNOSTIC METHODS | COMPUGEN USA INC (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006044694-A2 | METHODS AND COMPOSITIONS FOR TREATING A DISEASE CONDITION IN A SUBJECT | PALO ALTO INVESTORS (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2005107364-A2 | POLYNUCLEOTIDE, POLYPEPTIDES, AND DIAGNOSTIC METHODS | COMPUGEN USA, INC. (US) | 2005-11-17 | — | — | WO | disclosed |